tiprankstipranks
Blurbs

BTIG Sticks to Their Buy Rating for Cue Health (HLTH)

BTIG analyst Mark Massaro reiterated a Buy rating on Cue Health (HLTHResearch Report) yesterday and set a price target of $5.00. The company’s shares closed yesterday at $2.24.

According to TipRanks, Massaro is an analyst with an average return of -4.4% and a 39.60% success rate. Massaro covers the Healthcare sector, focusing on stocks such as BioNano Genomics, Cerus, and CareDx.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cue Health with a $5.38 average price target, which is a 140.18% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $5.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Cue Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $66.66 million and a GAAP net loss of $66.3 million. In comparison, last year the company earned a revenue of $193.59 million and had a net profit of $34.23 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cue Health Inc is a health technology company. It puts consumers in control of health information and places diagnostic information at the center of care. It enables people to manage health through real-time, actionable and connected health data. Further, it offers individuals, enterprises, government agencies and healthcare providers access to lab-quality diagnostic testing at home, at work, or at the point-of-care, all in a device that fits in the palm of hand.

Read More on HLTH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles